J
Jennifer A. Rothman
Researcher at Duke University
Publications - 63
Citations - 1425
Jennifer A. Rothman is an academic researcher from Duke University. The author has contributed to research in topics: Anemia & Population. The author has an hindex of 19, co-authored 55 publications receiving 1054 citations. Previous affiliations of Jennifer A. Rothman include Children's Hospital of Philadelphia & University of Medicine and Dentistry of New Jersey.
Papers
More filters
Journal ArticleDOI
Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia - TCD with Transfusions Changing to Hydroxyurea (TWiTCH): A multicentre, open-label, phase 3, non-inferiority trial
Russell E. Ware,Barry R. Davis,William H. Schultz,R. Clark Brown,Banu Aygun,Sharada A. Sarnaik,Isaac Odame,Beng Fuh,Alex George,William Owen,Lori Luchtman-Jones,Zora R. Rogers,Lee Hilliard,Cynthia Gauger,Connie M. Piccone,Margaret T. Lee,Janet L. Kwiatkowski,Sherron M. Jackson,Scott T. Miller,Carla W. Roberts,Matthew M. Heeney,Theodosia A. Kalfa,Stephen C. Nelson,Hamayun Imran,Kerri Nottage,Ofelia A. Alvarez,Melissa Rhodes,Alexis A. Thompson,Jennifer A. Rothman,Kathleen J. Helton,Donna R. Roberts,Jamie L. Coleman,Melanie J. Bonner,Abdullah Kutlar,Niren Patel,John C. Wood,Linda B. Piller,Peng Wei,Judy Luden,Nicole A. Mortier,Susan E. Stuber,Naomi L.C. Luban,Alan R. Cohen,Sara L. Pressel,Robert J. Adams +44 more
TL;DR: High-risk children with sickle cell anaemia and abnormal TCD velocities who have received at least 1 year of transfusions, and have no MRA-defined severe vasculopathy, hydroxycarbamide treatment can substitute for chronic transfusions to maintain TCD velocity and help to prevent primary stroke.
Journal ArticleDOI
Clinical spectrum of pyruvate kinase deficiency: data from the Pyruvate Kinase Deficiency Natural History Study.
Rachael F. Grace,Paola Bianchi,Eduard J. van Beers,Stefan W. Eber,Bertil Glader,Hassan M. Yaish,Jenny M. Despotovic,Jennifer A. Rothman,Mukta Sharma,Melissa M. McNaull,Elisa Fermo,Kimberly Lezon-Geyda,D. Holmes Morton,D. Holmes Morton,Ellis J. Neufeld,Satheesh Chonat,Nina Kollmar,Christine M. Knoll,Kevin H.M. Kuo,Janet L. Kwiatkowski,Dagmar Pospisilova,Yves D. Pastore,Alexis A. Thompson,Peter E. Newburger,Yaddanapudi Ravindranath,Winfred C. Wang,Marcin W. Wlodarski,Heng Wang,Susanne Holzhauer,Vicky R. Breakey,Joachim B. Kunz,Sujit Sheth,Melissa J. Rose,Heather A. Bradeen,Nolan Neu,Dongjing Guo,Hasan Al-Sayegh,Wendy B. London,Patrick G. Gallagher,Alberto Zanella,Wilma Barcellini +40 more
TL;DR: Although the risk of complications increases with severity of anemia and a genotype-phenotype relationship was observed, complications were common in all patients with PK deficiency and diagnostic testing for PK deficiency should be considered in patients with apparent congenital hemolytic anemia.
Journal ArticleDOI
Randomized Placebo-Controlled Crossover Trial of Tadalafil in Raynaud’s Phenomenon Secondary to Systemic Sclerosis
Elena Schiopu,Vivien Hsu,Ann Impens,Jennifer A. Rothman,Deborah A. McCloskey,Julianne E Wilson,Kristine Phillips,James R. Seibold +7 more
TL;DR: Tadalafil appears to be safe and well tolerated but lacks efficacy in comparison to placebo as a treatment for RP secondary to SSc and there were no statistically significant differences in Raynaud Condition Score (RCS), frequency of RP episodes, or duration ofRP episodes between treatment groups.
Journal ArticleDOI
Effects of hydroxyurea treatment for patients with hemoglobin SC disease.
Lori Luchtman-Jones,Lori Luchtman-Jones,Sara L. Pressel,Lee Hilliard,R. Clark Brown,Mary G. Smith,Alexis A. Thompson,Margaret T. Lee,Jennifer A. Rothman,Zora R. Rogers,William Owen,Hamayun Imran,Courtney D. Thornburg,Janet L. Kwiatkowski,Banu Aygun,Stephen C. Nelson,Carla W. Roberts,Cynthia Gauger,Connie M. Piccone,Theodosia A. Kalfa,Ofelia A. Alvarez,Kathryn L. Hassell,Barry R. Davis,Russell E. Ware +23 more
TL;DR: Multicenter data support the safety and potentially salutary effects of hydroxyurea treatment for HbSC disease; however, a multicenter, placebo‐controlled, Phase 3 clinical trial is needed to determine if hydroxyUREa therapy has efficacy for patients with Hb SC disease.
Journal ArticleDOI
Differential Requirement for the SAP-Fyn Interaction during NK T Cell Development and Function
Selene Nunez-Cruz,W. C. Janice Yeo,Jennifer A. Rothman,Priti Ojha,Hamid Bassiri,Marisa M. Juntilla,Dominique Davidson,André Veillette,Gary A. Koretzky,Kim E. Nichols +9 more
TL;DR: SAP appears to use differential signaling mechanisms in NKT cells, with optimal ontogeny requiring Fyn binding, while functional responses occur independently of this interaction.